In vivo protection by antimicrobial neutralizing Abs can require the contribution of effector functions mediated by Fc-Fcγ receptor (Fc-FcγR) interactions for optimal efficacy. In influenza, broadly neutralizing anti-hemagglutinin (anti-HA) stalk mAbs require Fc-FcγR interactions to mediate in vivo protection, but strain-specific anti-HA head mAbs do not. Whether this rule applies only to anti-stalk Abs or is applicable to any broadly neutralizing Ab (bNAb) against influenza is unknown. Here, we characterized the contribution of Fc-FcγR interactions during in vivo protection for a panel of 13 anti-HA mAbs, including bNAbs and non-neutralizing Abs, against both the stalk and head domains. All classes of broadly binding anti-HA mAbs required Fc-FcγR interactions to provide protection in vivo, including those mAbs that bind the HA head and those that do not neutralize virus in vitro. Further, a broadly neutralizing anti-neuraminidase (anti-NA) mAb also required FcγRs to provide protection in vivo, but a strain-specific anti-NA mAb did not. Thus, these findings suggest that the breadth of reactivity of anti-influenza Abs, regardless of their epitope, necessitates interactions with FcγRs on effector cell populations to mediate in vivo protection. These findings will guide the design of antiviral Ab therapeutics and inform vaccine design to elicit Abs with optimal binding properties and effector functions.
David J. DiLillo, Peter Palese, Patrick C. Wilson, Jeffrey V. Ravetch
Title and authors | Publication | Year |
---|---|---|
Administration of antigenically distinct influenza viral particle combinations as an influenza vaccine strategy
Zhu X, Luo Z, Leonard RA, Hamele CE, Spreng RL, Heaton NS |
PLOS Pathogens | 2025 |
Antiviral strategies against influenza virus: an update on approved and innovative therapeutic approaches
Bonomini A, Mercorelli B, Loregian A |
Cellular and Molecular Life Sciences: CMLS | 2025 |
A statistical framework for quantifying the nuclear export rate of influenza viral mRNAs
Miura M, Kiuchi N, Lau SY, Mok BW, Ushirogawa H, Naito T, Chen H, Saito M |
eLife | 2025 |
Cross-Reactive Fc-Mediated Antibody Responses to Influenza HA Stem Region in Human Sera Following Seasonal Vaccination
Nishiyama A, Nogimori T, Masuta Y, Matsuura T, Kase T, Kondo K, Ohfuji S, Nakagama Y, Kaku N, Nakagama S, Nitahara Y, Takahashi Y, Kakeya H, Kido Y, Fukushima W, Yamamoto T |
Vaccines | 2025 |
Conserved sites on the influenza H1 and H3 hemagglutinin recognized by human antibodies
Maurer DP, Vu M, Ferreira Ramos AS, Dugan HL, Khalife P, Geoghegan JC, Walker LM, Bajic G, Schmidt AG |
Science Advances | 2025 |
A monoclonal anti-hemagglutinin stem antibody modified with zanamivir protects against both influenza A and B viruses
Liu X, Balligand T, Le Gall C, Ploegh HL |
Proceedings of the National Academy of Sciences of the United States of America | 2025 |
Immune history shapes human antibody responses to H5N1 influenza viruses.
Garretson TA, Liu J, Li SH, Scher G, Santos JJS, Hogan G, Vieira MC, Furey C, Atkinson RK, Ye N, Ort JT, Kim K, Hernandez KA, Eilola T, Schultz DC, Cherry S, Cobey S, Hensley SE |
Nature medicine | 2025 |
Kinetic MUNANA assay reveals functionally relevant antibody epitopes on Influenza A virus neuraminidase.
Smirnov IV, Besavilla DF, Schön K, Axelsson H, Angeletti D |
Npj viruses | 2025 |
Multivalent next generation influenza virus vaccines protect against seasonal and pre-pandemic viruses.
Uno N, Ross TM |
Scientific Reports | 2024 |
High-resolution map of the Fc functions mediated by COVID-19-neutralizing antibodies
Paciello I, Maccari G, Pantano E, Andreano E, Rappuoli R |
Proceedings of the National Academy of Sciences | 2024 |
Applying valency-based immuno-selection to generate broadly cross-reactive antibodies against influenza hemagglutinins.
Hinke DM, Anderson AM, Katta K, Laursen MF, Tesfaye DY, Werninghaus IC, Angeletti D, Grødeland G, Bogen B, Braathen R |
Nature Communications | 2024 |
Prefusion-stabilized SARS-CoV-2 S2-only antigen provides protection against SARS-CoV-2 challenge
Hsieh CL, Leist SR, Miller EH, Zhou L, Powers JM, Tse AL, Wang A, West A, Zweigart MR, Schisler JC, Jangra RK, Chandran K, Baric RS, McLellan JS |
Nature Communications | 2024 |
Immunogenicity of chimeric hemagglutinins delivered by an orf virus vector platform against swine influenza virus
do Nascimento GM, de Oliveira PS, Butt SL, Diel DG |
Frontiers in immunology | 2024 |
Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination
Clark J, Hoxie I, Adelsberg DC, Sapse IA, Andreata-Santos R, Yong JS, Amanat F, Tcheou J, Raskin A, Singh G, González-Domínguez I, Edgar JE, Bournazos S, Sun W, Carreño JM, Simon V, Ellebedy AH, Bajic G, Krammer F |
2024 | |
Characterization of antibody-dependent cellular phagocytosis in patients infected with hepatitis C virus with different clinical outcomes.
Adhikari A, Abayasingam A, Brasher NA, Kim HN, Lord M, Agapiou D, Maher L, Rodrigo C, Lloyd AR, Bull RA, Tedla N |
Journal of Medical Virology | 2024 |
A Dual-domain Engineered Antibody for Efficient HBV Suppression and Immune Responses Restoration.
Jiang Y, Chen X, Ye X, Wen C, Xu T, Yu C, Ning W, Wang G, Xiang X, Liu X, Wang Y, Chen Y, Liu X, Shi C, Liu C, Yuan Q, Chen Y, Zhang T, Luo W, Xia N |
2024 | |
Broadly Reactive Nanobody Targeting the H3 Hemagglutinin of the Influenza A Virus.
Shcheblyakov DV, Voronina DV, Favorskaya IA, Esmagambetov IB, Alekseeva IA, Korobkova AI, Ryabova EI, Derkaev AA, Kan VY, Dzharullaeva AS, Tukhvatulin AI, Bandelyuk AS, Shmarov MM, Logunov DY, Gintsburg AL |
Acta Naturae | 2024 |
Eliciting a single amino acid change by vaccination generates antibody protection against group 1 and group 2 influenza A viruses
Ray R, Mohamed FA, Maurer DP, Huang J, Alpay BA, Ronsard L, Xie Z, Han J, Fernandez-Quintero M, Phan QA, Ursin RL, Vu M, Kirsch KH, Prum T, Rosado VC, Bracamonte-Moreno T, Okonkwo V, Bals J, McCarthy C, Nair U, Kanekiyo M, Ward A, Schmidt AG, Batista FD, Lingwood D |
Immunity | 2024 |
A chimeric haemagglutinin-based universal influenza virus vaccine boosts human cellular immune responses directed towards the conserved haemagglutinin stalk domain and the viral nucleoprotein
Bliss CM, Nachbagauer R, Mariottini C, Cuevas F, Feser J, Naficy A, Bernstein DI, Guptill J, Walter EB, Berlanda-Scorza F, Innis BL, García-Sastre A, Palese P, Krammer F, Coughlan L |
EBioMedicine | 2024 |
Nanoparticle display of neuraminidase elicits enhanced antibody responses and protection against influenza A virus challenge
Pascha MN, Ballegeer M, Roelofs MC, Meuris L, Albulescu IC, van Kuppeveld FJ, Hurdiss DL, Bosch BJ, Zeev-Ben-Mordehai T, Saelens X, de Haan CA |
npj Vaccines | 2024 |
Capsid virus-like particle display improves recombinant influenza neuraminidase antigen stability and immunogenicity in mice
Kang H, Martinez MR, Aves KL, Okholm AK, Wan H, Chabot S, Malik T, Sander AF, Daniels R |
iScience | 2024 |
Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions
Pierre CN, Adams LE, Higgins JS, Anasti K, Goodman D, Mielke D, Stanfield-Oakley S, Powers JM, Li D, Rountree W, Wang Y, Edwards RJ, Alam SM, Ferrari G, Tomaras GD, Haynes BF, Baric RS, Saunders KO |
PLoS pathogens | 2024 |
A broadly neutralizing human monoclonal antibody generated from transgenic mice immunized with HCMV particles limits virus infection and proliferation
Atanasoff KE, Parsons AJ, Ophir SI, Lurain N, Kraus T, Moran T, Duty JA, Tortorella D |
Journal of virology | 2024 |
Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine
Casazza JP, Hofstetter AR, Costner PJ, Holman LA, Hendel CS, Widge AT, Wu RL, Whalen WR, Cunningham J, Arthur A, Wang X, Ola A, Saunders J, Mendoza F, Novik L, Burgos Florez MC, Ortega-Villa AM, Apte PJ, Strom L, Wang L, Imam M, Basappa M, Naisan M, Castro M, Trost JF, Narpala SR, Vanderven HA, Yamshchikov GV, Berkowitz NM, Gordon IJ, Plummer SH, Wycuff DL, Vazquez S, Gillespie RA, Creanga A, Adams WC, Carlton K, Gall JG, McDermott AB, Serebryannyy LA, Houser KV, Koup RA, Graham BS, Ledgerwood JE, Mascola JR, Pierson TC, Andrews SF, Kanekiyo M, Dropulic LK |
NPJ Vaccines | 2024 |
A comprehensive review of influenza B virus, its biological and clinical aspects
Ashraf MA, Raza MA, Amjad MN, ud Din G, Yue L, Shen B, Chen L, Dong W, Xu H, Hu Y |
Frontiers in Microbiology | 2024 |
Intranasal administration of octavalent next-generation influenza vaccine elicits protective immune responses against seasonal and pre-pandemic viruses
Uno N, Ebensen T, Guzman CA, Ross TM |
Journal of Virology | 2024 |
The lipid globotriaosylceramide promotes germinal center B cell responses and antiviral immunity
Sharma P, Zhang X, Ly K, Zhang Y, Hu Y, Yongxin Ye A, Hu J, Kim JH, Lou M, Wang C, Celuzza Q, Kondo Y, Furukawa K, Bundle DR, Furukawa K, Alt FW, Winau F |
Science (New York, N.Y.) | 2024 |
Isolation of human antibodies against influenza B neuraminidase and mechanisms of protection at the airway interface
Wolters RM, Ferguson J, Nuñez IA, Chen EE, Sornberger T, Myers L, Oeverdieck S, Raghavan SS, Kona C, Handal LS, Esilu TE, Davidson E, Doranz BJ, Engdahl TB, Kose N, Williamson LE, Creech CB, Gibson-Corley KN, Ward AB, Crowe JE Jr |
Immunity | 2024 |
Improved influenza vaccine responses after expression of multiple viral glycoproteins from a single mRNA.
Leonard RA, Burke KN, Spreng RL, Macintyre AN, Tam Y, Alameh MG, Weissman D, Heaton NS |
Nature communications | 2024 |
Immune history shapes human antibody responses to H5N1 influenza viruses
Garretson TA, Liu J, Li SH, Scher G, Santos JJ, Hogan G, Vieira MC, Furey C, Atkinson RK, Ye N, Ort J, Kim K, Hernandez KA, Eilola T, Schultz DC, Cherry S, Cobey S, Hensley SE |
medRxiv | 2024 |
A multi-antigen vaccinia vaccine broadly protected mice against SARS-CoV-2 and influenza A virus while also targeting SARS-CoV-1 and MERS-CoV
Gao N, Yang T, Dong L, Tang W, Cao K, Ding L, Zhu C, Bai S, Xia A, Zhu Y, Zhao C, Peng H, Xu J, Zhang X |
Frontiers in Immunology | 2024 |
Fc‐FcγR interactions during infections: From neutralizing antibodies to antibody‐dependent enhancement
Edgar JE, Bournazos S |
Immunological Reviews | 2024 |
Induction of Fc-dependent functional antibodies against different variants of SARS-CoV-2 varies by vaccine type and prior infection
Harris AW, Kurtovic L, Nogueira J, Bouzas I, Opi DH, Wines BD, Lee WS, Hogarth PM, Poumbourios P, Drummer HE, Valim C, Porto LC, Beeson JG |
Communications Medicine | 2024 |
Antibody-mediated control mechanisms of viral infections
Mackin SR, Sariol A, Diamond MS |
Immunological reviews | 2024 |
Transforming Vaccinology
Rappuoli R, Alter G, Pulendran B |
Cell | 2024 |
Sialylated IgG induces the transcription factor REST in alveolar macrophage to protect against lung inflammation and severe influenza disease
Chakraborty S, Cheng BY, Edwards DL, Gonzalez JC, Chiu DK, Zheng H, Scallan C, Guo X, Tan GS, Coffey GP, Conley PB, Hume PS, Janssen WJ, Byers DE, Mudd PA, Taubenberger J, Memoli M, Davis MM, Chua KF, Diamond MS, Andreakos E, Khatri P, Wang TT |
Immunity | 2024 |
Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination
Clark JJ, Hoxie I, Adelsberg DC, Sapse IA, Andreata-Santos R, Yong JS, Amanat F, Tcheou J, Raskin A, Singh G, González-Domínguez I, Edgar JE, Bournazos S, Sun W, Carreño JM, Simon V, Ellebedy AH, Bajic G, Krammer F |
Cell reports | 2024 |
Understanding the treatment benefit of hyperimmune anti-influenza intravenous immunoglobulin (Flu-IVIG) for severe human influenza
Hillary Vanderven, Deborah Wentworth, Win Min Han, Heidi Peck, Ian Barr, Richard Davey, John Beigel, Dominic Dwyer, Mamta K. Jain, Brian Angus, Christian Brandt, Analia Mykietiuk, Matthew Law, Jim Neaton, Stephen Kent |
JCI Insight | 2023 |
Enhancing the protection of influenza virus vaccines with BECC TLR4 adjuvant in aged mice.
Haupt R, Baracco L, Harberts EM, Loganathan M, Kerstetter LJ, Krammer F, Coughlan L, Ernst RK, Frieman MB |
Scientific Reports | 2023 |
Systems serology-based comparison of antibody effector functions induced by adjuvanted vaccines to guide vaccine design.
Loos C, Coccia M, Didierlaurent AM, Essaghir A, Fallon JK, Lauffenburger D, Luedemann C, Michell A, van der Most R, Zhu AL, Alter G, Burny W |
npj Vaccines | 2023 |
ADCC: An underappreciated correlate of cross-protection against influenza?
de Vries RD, Hoschler K, Rimmelzwaan GF |
Frontiers in immunology | 2023 |
IgG1 Is the Optimal Subtype for Treating Atherosclerosis by Inducing M2 Macrophage Differentiation, and Is Independent of the FcγRIIA Gene Polymorphism.
Duan R, Liu Y, Tang D, Lin R, Huang J, Zhao M |
International journal of molecular sciences | 2023 |
Bivalent vaccines effectively protect mice against influenza A and respiratory syncytial viruses
Raman SN, Zetner A, Hashem AM, Patel D, Wu J, Gravel C, Gao J, Zhang W, Pfeifle A, Tamming L, Parikh K, Cao J, Tam R, Safronetz D, Chen W, Johnston MJ, Wang L, Sauve S, Rosu-Myles M, Domselaar GV, Li X |
Emerging Microbes & Infections | 2023 |
Enhancing the therapeutic activity of hyperimmune IgG against chikungunya virus using FcγRIIIa affinity chromatography
Fox JM, Roy V, Gunn BM, Bolton GR, Fremont DH, Alter G, Diamond MS, Boesch AW |
Frontiers in immunology | 2023 |
Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies
Struble EB, Rawson JM, Stantchev T, Scott D, Shapiro MA |
Pharmaceutics | 2023 |
A pan-influenza antibody inhibiting neuraminidase via receptor mimicry.
Momont C, Dang HV, Zatta F, Hauser K, Wang C, di Iulio J, Minola A, Czudnochowski N, De Marco A, Branch K, Donermeyer D, Vyas S, Chen A, Ferri E, Guarino B, Powell AE, Spreafico R, Yim SS, Balce DR, Bartha I, Meury M, Croll TI, Belnap DM, Schmid MA, Schaiff WT, Miller JL, Cameroni E, Telenti A, Virgin HW, Rosen LE, Purcell LA, Lanzavecchia A, Snell G, Corti D, Pizzuto MS |
Nature | 2023 |
Fc-Effector-Independent in vivo Activity of a Potent Influenza B Neuraminidase Broadly Neutralizing Antibody
Khalil AM, Piepenbrink MS, Markham I, Basu M, Martinez-Sobrido L, Kobie JJ |
Viruses | 2023 |
An armed anti-immunoglobulin light chain nanobody protects mice against influenza A and B infections
Liu X, Balligand T, Carpenet C, Ploegh HL |
Science Immunology | 2023 |
Neuraminidase delivered as an APC-targeted DNA vaccine induces protective antibodies against influenza
Werninghaus IC, Hinke DM, Fossum E, Bogen B, Braathen R |
Molecular Therapy | 2023 |
Single-dose mucosal replicon-particle vaccine protects against lethal Nipah virus infection up to 3 days after vaccination.
Welch SR, Spengler JR, Genzer SC, Coleman-McCray JD, Harmon JR, Sorvillo TE, Scholte FEM, Rodriguez SE, O'Neal TJ, Ritter JM, Ficarra G, Davies KA, Kainulainen MH, Karaaslan E, Bergeron É, Goldsmith CS, Lo MK, Nichol ST, Montgomery JM, Spiropoulou CF |
Science Advances | 2023 |
Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions
Pierre CN, Adams LE, Anasti K, Goodman D, Stanfield-Oakley S, Powers JM, Li D, Rountree W, Wang Y, Edwards RJ, Munir Alam S, Ferrari G, Tomaras GD, Haynes BF, Baric RS, Saunders KO |
2023 | |
Polyfunctional antibodies: a path towards precision vaccines for vulnerable populations
Purcell RA, Theisen RM, Arnold KB, Chung AW, Selva KJ |
Frontiers in immunology | 2023 |
Antibody-mediated NK cell activation as a correlate of immunity against influenza infection.
Boudreau CM, Burke JS 4th, Yousif AS, Sangesland M, Jastrzebski S, Verschoor C, Kuchel G, Lingwood D, Kleanthous H, De Bruijn I, Landolfi V, Sridhar S, Alter G |
Nature Communications | 2023 |
Designed nanoparticles elicit cross-reactive antibody responses to conserved influenza virus hemagglutinin stem epitopes
McCraw DM, Myers ML, Gulati NM, Prabhakaran M, Brand J, Andrews S, Gallagher JR, Maldonado-Puga S, Kim AJ, Torian U, Syeda H, Boyoglu-Barnum S, Kanekiyo M, McDermott AB, Harris AK |
PLoS pathogens | 2023 |
Vaccine-induced neutralizing antibody responses to seasonal influenza virus H1N1 strains are not enhanced during subsequent pandemic H1N1 infection
Mooij P, Mortier D, Aartse A, Murad AB, Correia R, Roldão A, Alves PM, Fagrouch Z, Eggink D, Stockhofe N, Engelhardt OG, Verschoor EJ, van Gils MJ, Bogers WM, Carrondo MJ, Remarque EJ, Koopman G |
Frontiers in immunology | 2023 |
Protective mechanisms of nonneutralizing antiviral antibodies
Chandler TL, Yang A, Otero CE, Permar SR, Caddy SL |
PLoS pathogens | 2023 |
Human anti-N1 monoclonal antibodies elicited by pandemic H1N1 virus infection broadly inhibit HxN1 viruses in vitro and in vivo
Hansen L, McMahon M, Turner HL, Zhu X, Turner JS, Ozorowski G, Stadlbauer D, Vahokoski J, Schmitz AJ, Rizk AA, Alsoussi WB, Strohmeier S, Yu W, Choreño-Parra JA, Jiménez-Alvarez L, Cruz-Lagunas A, Zúñiga J, Mudd PA, Cox RJ, Wilson IA, Ward AB, Ellebedy AH, Krammer F |
Immunity | 2023 |
Antibodies elicited in humans upon chimeric hemagglutinin-based influenza virus vaccination confer FcγR-dependent protection in vivo
Edgar JE, Trezise S, Anthony RM, Krammer F, Palese P, Ravetch JV, Bournazos S |
Proceedings of the National Academy of Sciences | 2023 |
Characterization of non-neutralizing human monoclonal antibodies that target the M1 and NP of influenza A viruses
Rijnink WF, Stadlbauer D, Puente-Massaguer E, Okba NM, Kirkpatrick Roubidoux E, Strohmeier S, Mudd PA, Schmitz A, Ellebedy A, McMahon M, Krammer F |
Journal of virology | 2023 |
Fc-mediated functions and the treatment of severe respiratory viral infections with passive immunotherapy - a balancing act.
Vanderven HA, Kent SJ |
Frontiers in immunology | 2023 |
Difference in respiratory syncytial virus-specific Fc-mediated antibody effector functions between children and adults.
Lakerveld AJ, Gelderloos AT, Schepp RM, de Haan CAM, van Binnendijk RS, Rots NY, van Beek J, van Els CACM, van Kasteren PB |
Clinical & Experimental Immunology | 2023 |
From bench to bedside via bytes: Multi-omic immunoprofiling and integration using machine learning and network approaches.
Xiao H, Rosen A, Chhibbar P, Moise L, Das J |
Human Vaccines & Immunotherapeutics | 2023 |
Development of Self-Assembled Protein Nanocage Spatially Functionalized with HA Stalk as a Broadly Cross-Reactive Influenza Vaccine Platform.
Park J, Champion JA |
ACS Nano | 2023 |
Protective human antibodies against a conserved epitope in pre- and postfusion influenza hemagglutinin
Finney J, Moseman AP, Kong S, Watanabe A, Song S, Walsh RM Jr, Kuraoka M, Kotaki R, Moseman EA, McCarthy KR, Liao D, Liang X, Nie X, Lavidor O, Abbott R, Harrison SC, Kelsoe G |
Proceedings of the National Academy of Sciences | 2023 |
Protective efficacy of a universal influenza mRNA vaccine against the challenge of H1 and H5 influenza A viruses in mice.
Li Y, Wang X, Zeng X, Ren W, Liao P, Zhu B |
2023 | |
Adenovirus-based vaccines—a platform for pandemic preparedness against emerging viral pathogens
L Coughlan, E Kremer, D Shayakhmetov |
Molecular Therapy | 2022 |
A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice
C Bliss, A Freyn, T Caniels, V Leyva-Grado, R Nachbagauer, W Sun, G Tan, V Gillespie, M McMahon, F Krammer, A Hill, P Palese, L Coughlan |
Molecular Therapy | 2022 |
Antibodies directed towards neuraminidase restrict influenza virus replication in primary human bronchial epithelial cells
A Smet, J Catani, T Ysenbaert, A Gonçalves, H Kleanthous, T Vogel, X Saelens, E Job, S Herfst |
PloS one | 2022 |
Mucosal immune responses to infection and vaccination in the respiratory tract
R Mettelman, E Allen, P Thomas |
Immunity | 2022 |
Fc-Mediated Functions of Porcine IgG Subclasses
Paudyal B, Mwangi W, Rijal P, Schwartz JC, Noble A, Shaw A, Sealy JE, Bonnet-Di Placido M, Graham SP, Townsend A, Hammond JA, Tchilian E |
Frontiers in immunology | 2022 |
Functional antibody-dependent cell mediated cytotoxicity (ADCC) responses to vaccine and circulating influenza strains following vaccination.
Chen X, Sun HY, Lee CY, Rostad CA, Trost J, Abreu RB, Carlock MA, Wilson JR, Gansebom S, Ross TM, Steinhauer DA, Anderson EJ, Anderson LJ |
Virology | 2022 |
Targeting Xcr1 on Dendritic Cells Rapidly Induce Th1-Associated Immune Responses That Contribute to Protection Against Influenza Infection
Tesfaye DY, Bobic S, Lysén A, Huszthy PC, Gudjonsson A, Braathen R, Bogen B, Fossum E |
Frontiers in immunology | 2022 |
Evaluation of strategies to modify Anti-SARS-CoV-2 monoclonal antibodies for optimal functionality as therapeutics
House RV, Broge TA, Suscovich TJ, Snow DM, Tomic MT, Nonet G, Bajwa K, Zhu G, Martinez Z, Hackett K, Earnhart CG, Dorsey NM, Hopkins SA, Natour DS, Davis HD, Anderson MS, Gainey MR, Cobb RR |
PloS one | 2022 |
Omicron variant Spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines.
Bartsch YC, Tong X, Kang J, Avendaño MJ, Serrano EF, García-Salum T, Pardo-Roa C, Riquelme A, Cai Y, Renzi I, Stewart-Jones G, Chen B, Medina RA, Alter G |
Science Translational Medicine | 2022 |
Dissecting Fc signatures of protection in neonates following maternal influenza vaccination in a placebo-controlled trial
Boudreau CM, Burke JS IV, Shuey KD, Wolf C, Katz J, Tielsch J, Khatry S, LeClerq SC, Englund JA, Chu HY, Alter G |
Cell Reports | 2022 |
Correlates of protection against SARS-CoV-2 infection and COVID-19 disease.
Goldblatt D, Alter G, Crotty S, Plotkin SA |
Immunological Reviews | 2022 |
Fc-Dependent Immunomodulation Induced by Antiviral Therapeutic Antibodies: New Perspectives for Eliciting Protective Immune Responses.
Pelegrin M, Marsile-Medun S, Abba-Moussa D, Souchard M, Naranjo-Gomez M |
2022 | |
Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains.
Case JB, Mackin S, Errico JM, Chong Z, Madden EA, Whitener B, Guarino B, Schmid MA, Rosenthal K, Ren K, Dang HV, Snell G, Jung A, Droit L, Handley SA, Halfmann PJ, Kawaoka Y, Crowe JE Jr, Fremont DH, Virgin HW, Loo YM, Esser MT, Purcell LA, Corti D, Diamond MS |
Nature Communications | 2022 |
A Novel Neuraminidase Virus-Like Particle Vaccine Offers Protection Against Heterologous H3N2 Influenza Virus Infection in the Porcine Model.
Pliasas VC, Menne Z, Aida V, Yin JH, Naskou MC, Neasham PJ, North JF, Wilson D, Horzmann KA, Jacob J, Skountzou I, Kyriakis CS |
Frontiers in immunology | 2022 |
Progress towards the Development of a Universal Influenza Vaccine
Wang WC, Sayedahmed EE, Sambhara S, Mittal SK |
Viruses | 2022 |
Hemagglutinin stalk-binding antibodies enhance effectiveness of neuraminidase inhibitors against influenza via Fc-dependent effector functions
Zhang A, Chaudhari H, Agung Y, D\u2019Agostino MR, Ang JC, Tugg Y, Miller MS |
Cell reports. Medicine | 2022 |
Assessment of Fcγ receptor-dependent binding of influenza hemagglutinin vaccine-induced antibodies in a non-human primate model
Masuta Y, Takahama S, Nogimori T, Moriyama S, Takahashi Y, Yamamoto T |
iScience | 2022 |
Modulating cholesterol-rich lipid rafts to disrupt influenza A virus infection
Li YJ, Chen CY, Yang JH, Chiu YF |
Frontiers in immunology | 2022 |
Universal antibody targeting the highly conserved fusion peptide provides cross-protection in mice.
Muralidharan A, Gravel C, Harris G, Hashem AM, Zhang W, Safronetz D, Van Domselaar G, Krammer F, Sauve S, Rosu-Myles M, Wang L, Chen W, Li X |
Human Vaccines & Immunotherapeutics | 2022 |
A broadly protective human monoclonal antibody targeting the sialidase activity of influenza A and B virus neuraminidases.
Yasuhara A, Yamayoshi S, Kiso M, Sakai-Tagawa Y, Okuda M, Kawaoka Y |
Nature Communications | 2022 |
Cross-Reactive Fc-Fused Single-Domain Antibodies to Hemagglutinin Stem Region Protect Mice from Group 1 Influenza a Virus Infection
Voronina DV, Shcheblyakov DV, Favorskaya IA, Esmagambetov IB, Dzharullaeva AS, Tukhvatulin AI, Zubkova OV, Popova O, Kan VY, Bandelyuk AS, Shmarov MM, Logunov DY, Naroditskiy BS, Gintsburg AL |
Viruses | 2022 |
Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection
Zhang A, Stacey HD, D\u2019Agostino MR, Tugg Y, Marzok A, Miller MS |
Nature reviews. Immunology | 2022 |
Co-immunization with hemagglutinin stem immunogens elicits cross-group neutralizing antibodies and broad protection against influenza A viruses
Moin SM, Boyington JC, Boyoglu-Barnum S, Gillespie RA, Cerutti G, Cheung CS, Cagigi A, Gallagher JR, Brand J, Prabhakaran M, Tsybovsky Y, Stephens T, Fisher BE, Creanga A, Ataca S, Rawi R, Corbett KS, Crank MC, Karlsson Hedestam GB, Gorman J, McDermott AB, Harris AK, Zhou T, Kwong PD, Shapiro L, Mascola JR, Graham BS, Kanekiyo M |
Immunity | 2022 |
Longevity and Mechanism of Heterosubtypic Protection Induced by M2SR (M2-Deficient Single-Replication) Live Influenza Virus Vaccine in Mice
Sarawar S, Gabaglia CR, Sanchez A, Hatta Y, Dias P, Neumann G, Kawaoka Y, Bilsel P |
Human vaccines | 2022 |
Nucleoside-Modified mRNA-Based Influenza Vaccines Circumvent Problems Associated with H3N2 Vaccine Strain Egg Adaptation
Gouma S, Furey C, Santos JJ, Parkhouse K, Weirick M, Muramatsu H, Pardi N, Fan SH, Weissman D, Hensley SE |
Journal of virology | 2022 |
Antivirals Targeting the Neuraminidase
Gubareva L, Mohan T |
Cold Spring Harbor Perspectives in Medicine | 2022 |
Understanding Host Immunity and the Gut Microbiota Inspires the New Development of Vaccines and Adjuvants
K Yakabe, J Uchiyama, M Akiyama, YG Kim |
Pharmaceutics | 2021 |
Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses
LJ Kerstetter, S Buckley, CM Bliss, L Coughlan |
Frontiers in immunology | 2021 |
On the road to ending the COVID-19 pandemic: Are we there yet?
JB Case, ES Winkler, JM Errico, MS Diamond |
Virology | 2021 |
There Is Strength in Numbers: Quantitation of Fc Gamma Receptors on Murine Tissue-Resident Macrophages
C Vorsatz, N Friedrich, F Nimmerjahn, M Biburger |
International journal of molecular sciences | 2021 |
Isotype-Specific Fc Effector Functions Enhance Antibody-Mediated Rift Valley Fever Virus Protection In Vivo
HN Cartwright, DJ Barbeau, AK McElroy, RE Dutch |
mSphere | 2021 |
Neutrophils and Influenza: A Thin Line between Helpful and Harmful
ST George, J Lai, J Ma, HD Stacey, MS Miller, CE Mullarkey |
Human vaccines | 2021 |
Antibody Focusing to Conserved Sites of Vulnerability: The Immunological Pathways for ‘Universal’ Influenza Vaccines
M Sangesland, D Lingwood |
Human vaccines | 2021 |
The Next Generation of Influenza Vaccines: Towards a Universal Solution
CL McMillan, PR Young, D Watterson, KJ Chappell |
Human vaccines | 2021 |
B Cell Responses against Influenza Viruses: Short-Lived Humoral Immunity against a Life-Long Threat
JJ Guthmiller, HA Utset, PC Wilson |
Viruses | 2021 |
Synergistic effect of non-neutralizing antibodies and interferon-γ for cross-protection against influenza
M Shibuya, S Tamiya, A Kawai, T Hirai, M Cragg, Y Yoshioka |
iScience | 2021 |
Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection
BM Gunn, S Bai |
Human Vaccines & Immunotherapeutics | 2021 |
Broadly neutralizing antibodies target a haemagglutinin anchor epitope
J Guthmiller, J Han, H Utset, L Li, L Lan, C Henry, C Stamper, M McMahon, G ODell, M Fernández-Quintero, A Freyn, F Amanat, O Stovicek, L Gentles, S Richey, A de la Peña, V Rosado, H Dugan, N Zheng, M Tepora, D Bitar, S Changrob, S Strohmeier, M Huang, A García-Sastre, K Liedl, J Bloom, R Nachbagauer, P Palese, F Krammer, L Coughlan, A Ward, P Wilson |
Nature | 2021 |
Unique structural solution from a VH3-30 antibody targeting the hemagglutinin stem of influenza A viruses
WD Harshbarger, D Deming, GJ Lockbaum, N Attatippaholkun, M Kamkaew, S Hou, M Somasundaran, JP Wang, RW Finberg, QK Zhu, CA Schiffer, WA Marasco |
Nature Communications | 2021 |
Influenza hemagglutinin-specific IgA Fc-effector functionality is restricted to stalk epitopes
AW Freyn, J Han, JJ Guthmiller, MJ Bailey, K Neu, HL Turner, VC Rosado, V Chromikova, M Huang, S Strohmeier, ST Liu, V Simon, F Krammer, AB Ward, P Palese, PC Wilson, R Nachbagauer |
Proceedings of the National Academy of Sciences | 2021 |
Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection
CJ Batty, MT Heise, EM Bachelder, KM Ainslie |
Advanced Drug Delivery Reviews | 2021 |
Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions
AR Shiakolas, KJ Kramer, D Wrapp, SI Richardson, A Schäfer, S Wall, N Wang, K Janowska, KA Pilewski, R Venkat, R Parks, NP Manamela, N Raju, EF Fechter, CM Holt, N Suryadevara, RE Chen, DR Martinez, RS Nargi, RE Sutton, JE Ledgerwood, BS Graham, MS Diamond, BF Haynes, P Acharya, RH Carnahan, JE Crowe, RS Baric, L Morris, JS McLellan, IS Georgiev |
Reproduction | 2021 |
Broad Reactivity Single Domain Antibodies against Influenza Virus and Their Applications to Vaccine Potency Testing and Immunotherapy
AT Yep, Y Takeuchi, OG Engelhardt, SE Hufton |
Biomolecules | 2021 |
Development of a Macrophage-Based ADCC Assay
MB Uccellini, S Aslam, ST Liu, F Alam, A García-Sastre |
Human vaccines | 2021 |
Tackling COVID-19 with neutralizing monoclonal antibodies
D Corti, LA Purcell, G Snell, D Veesler |
Cell | 2021 |
Decay of Fc-dependent antibody functions after mild to moderate COVID-19
WS Lee, KJ Selva, SK Davis, BD Wines, A Reynaldi, R Esterbauer, HG Kelly, ER Haycroft, HX Tan, JA Juno, AK Wheatley, PM Hogarth, D Cromer, MP Davenport, AW Chung, SJ Kent |
Reproduction | 2021 |
Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection
ES Winkler, P Gilchuk, J Yu, AL Bailey, RE Chen, Z Chong, SJ Zost, H Jang, Y Huang, JD Allen, JB Case, RE Sutton, RH Carnahan, TL Darling, AC Boon, M Mack, RD Head, TM Ross, JE Crowe, MS Diamond |
Cell | 2021 |
A non-neutralizing antibody broadly protects against influenza virus infection by engaging effector cells
YA Ko, YH Yu, YF Wu, YC Tseng, CL Chen, KS Goh, HY Liao, TH Chen, TJ Cheng, AS Yang, CH Wong, C Ma, KI Lin, SL Klein |
PLoS pathogens | 2021 |
Immune Responses Elicited by Live Attenuated Influenza Vaccines as Correlates of Universal Protection against Influenza Viruses
YH Jang, BL Seong |
Human vaccines | 2021 |
Stabilized coronavirus spike stem elicits a broadly protective antibody
CL Hsieh, AP Werner, SR Leist, LJ Stevens, E Falconer, JA Goldsmith, CW Chou, OM Abiona, A West, K Westendorf, K Muthuraman, EJ Fritch, KH Dinnon, A Schäfer, MR Denison, JD Chappell, RS Baric, BS Graham, KS Corbett, JS McLellan |
Cell Reports | 2021 |
Requirement of Fc-Fc Gamma Receptor Interaction for Antibody-Based Protection against Emerging Virus Infections
SP Keeler, JM Fox |
Viruses | 2021 |
IgA potentiates NETosis in response to viral infection
HD Stacey, D Golubeva, A Posca, JC Ang, KE Novakowski, MA Zahoor, C Kaushic, E Cairns, DM Bowdish, CE Mullarkey, MS Miller |
Proceedings of the National Academy of Sciences | 2021 |
Mice with diverse microbial exposure histories as a model for preclinical vaccine testing
JK Fiege, KE Block, MJ Pierson, H Nanda, FK Shepherd, CK Mickelson, JM Stolley, WE Matchett, S Wijeyesinghe, DK Meyerholz, V Vezys, SS Shen, SE Hamilton, D Masopust, RA Langlois |
Cell Host & Microbe | 2021 |
Fc-Independent Protection from SARS-CoV-2 Infection by Recombinant Human Monoclonal Antibodies
T Noy-Porat, A Edri, R Alcalay, E Makdasi, D Gur, M Aftalion, Y Evgy, A Beth-Din, Y Levy, E Epstein, O Radinsky, A Zauberman, S Lazar, S Yitzhaki, H Marcus, A Porgador, R Rosenfeld, O Mazor |
Antibodies | 2021 |
Epigallocatechin-3-Gallate as a Novel Vaccine Adjuvant
Y Cheong, M Kim, J Ahn, H Oh, J Lim, W Chae, SW Yang, MS Kim, JE Yu, S Byun, YH Jang, BL Seong |
Frontiers in immunology | 2021 |
Matrix M Adjuvanted H5N1 Vaccine Elicits Broadly Neutralizing Antibodies and Neuraminidase Inhibiting Antibodies in Humans That Correlate With In Vivo Protection
F Zhou, L Hansen, G Pedersen, G Grødeland, R Cox |
Frontiers in immunology | 2021 |
Cross-reactive antibodies after SARS-CoV-2 infection and vaccination
M Grobben, K van der Straten, PJ Brouwer, M Brinkkemper, P Maisonnasse, N Dereuddre-Bosquet, B Appelman, AH Lavell, LA van Vught, JA Burger, M Poniman, M Oomen, D Eggink, TP Bijl, HD van Willigen, E Wynberg, BJ Verkaik, OJ Figaroa, PJ de Vries, TM Boertien, MK Bomers, JJ Sikkens, RL Grand, MD de Jong, M Prins, AW Chung, GJ de Bree, RW Sanders, MJ van Gils |
eLife | 2021 |
Fc-engineered antibody therapeutics with improved efficacy against COVID-19
Jeffrey Ravetch, Rachel Yamin, Andrew Jones, Hans-Heinrich Hoffmann, Kevin Kao, Rebecca Francis, Timothy Sheahan, Ralph Baric, Charles Rice, Stylianos Bournazos |
Research square | 2021 |
Influenza Neuraminidase Characteristics and Potential as a Vaccine Target
S Creytens, M Pascha, M Ballegeer, X Saelens, C de Haan |
Frontiers in immunology | 2021 |
Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters
W Su, S Sia, A Schmitz, T Bricker, T Starr, A Greaney, J Turner, B Mohammed, Z Liu, K Choy, T Darling, A Joshi, K Cheng, A Wong, H Harastani, J Nicholls, S Whelan, J Bloom, H Yen, A Ellebedy, A Boon, G Pier |
mBio | 2021 |
The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2)
N Beeraka, S Tulimilli, M Karnik, S Sadhu, R Pragada, G Aliev, S Madhunapantula, J Lu |
BioMed Research International | 2021 |
Intranasal vaccination with influenza HA/GO-PEI nanoparticles provides immune protection against homo- and heterologous strains
C Dong, Y Wang, G Gonzalez, Y Ma, Y Song, S Wang, S Kang, R Compans, B Wang |
Proceedings of the National Academy of Sciences | 2021 |
Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies
J Dufloo, L Grzelak, I Staropoli, Y Madec, L Tondeur, F Anna, S Pelleau, A Wiedemann, C Planchais, J Buchrieser, R Robinot, M Ungeheuer, H Mouquet, P Charneau, M White, Y Lévy, B Hoen, A Fontanet, O Schwartz, T Bruel |
Cell reports. Medicine | 2021 |
Strategies Targeting Hemagglutinin as a Universal Influenza Vaccine
B Bullard, E Weaver |
Human vaccines | 2021 |
Roles of the Fc Receptor γ-Chain in Inducing Protective Immune Responses after Heterologous Vaccination against Respiratory Syncytial Virus Infection
H Hwang, Y Lee, K Kim, H Seo, K Yang, H Cho, S Kang |
Human vaccines | 2021 |
Persistently high antibody responses after AS03-adjuvanted H1N1pdm09 vaccine: Dissecting the HA specific antibody response
A Madsen, Å Jul-Larsen, M Trieu, F Krammer, R Cox |
npj Vaccines | 2021 |
Development of mouse monoclonal antibody for detecting hemagglutinin of avian influenza A(H7N9) virus and preventing virus infection
Y Chiang, C Li, H Su, K Hsieh, C Weng, H Chen, S Chang |
Applied Microbiology and Biotechnology | 2021 |
Adjuvant Selection for Influenza and RSV Prefusion Subunit Vaccines
A Isaacs, Z Li, S Cheung, D Wijesundara, C McMillan, N Modhiran, P Young, C Ranasinghe, D Watterson, K Chappell |
Human vaccines | 2021 |
SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?
S Chakraborty, V Mallajosyula, C Tato, G Tan, T Wang |
Advanced Drug Delivery Reviews | 2021 |
An influenza HA stalk reactive polymeric IgA antibody exhibits anti-viral function regulated by binary interaction between HA and the antibody
K Sano, S Saito, T Suzuki, O Kotani, A Ainai, E van Riet, K Tabata, K Saito, Y Takahashi, M Yokoyama, H Sato, T Maruno, K Usami, S Uchiyama, K Ogawa-Goto, H Hasegawa, V Huber |
PloS one | 2021 |
Human anti-neuraminidase antibodies reduce airborne transmission of clinical influenza virus isolates in the guinea pig model
J Tan, G O'Dell, M Hernandez, E Sordillo, Z Kahn, D Kriti, H van Bakel, A Ellebedy, P Wilson, V Simon, F Krammer, M McMahon |
Journal of virology | 2021 |
Engineered Nanoparticulate Vaccines to Combat Recurring and Pandemic Influenza Threats
Dong C, Wang BZ |
2021 | |
Enhanced cross protection by hetero prime-boost vaccination with recombinant influenza viruses containing chimeric hemagglutinin-M2e epitopes
Park BR, Subbiah J, Kim KH, Kwon YM, Oh J, Kim MC, Shin CH, Seong BL, Kang SM |
Virology | 2021 |
Original Antigenic Sin: How Original? How Sinful?
Yewdell JW, Santos JJS |
Cold Spring Harbor Perspectives in Medicine | 2021 |
Preserved Omicron Spike specific antibody binding and Fc-recognition across COVID-19 vaccine platforms
Bartsch Y, Tong X, Kang J, José Avendaño M, Serrano EF, García-Salum T, Pardo-Roa C, Riquelme A, Medina RA, Alter G |
2021 | |
Influenza infected newborn and adult monkeys exhibit a strong primary antibody response to hemagglutinin stem
Elene A. Clemens, Davide Angeletti, Beth C. Holbrook, Masaru Kanekiyo, Matthew J. Jorgensen, Barney S. Graham, Jonathan W. Yewdell, Martha A. Alexander-Miller |
JCI Insight | 2020 |
The role of IgG Fc receptors in antibody-dependent enhancement
S Bournazos, A Gupta, JV Ravetch |
Nature Reviews Immunology | 2020 |
Airway Delivery of Anti-influenza Monoclonal Antibodies Results in Enhanced Antiviral Activities and Enables Broad-Coverage Combination Therapies
A Vigil, N Frias-Staheli, T Carabeo, M Wittekind, MT Heise |
Journal of virology | 2020 |
Recombinant Influenza Vaccines: Saviors to Overcome Immunodominance
NR Mathew, D Angeletti |
Frontiers in immunology | 2020 |
Establishment of a Pig Influenza Challenge Model for Evaluation of Monoclonal Antibody Delivery Platforms
A McNee, TR Smith, B Holzer, B Clark, E Bessell, G Guibinga, H Brown, K Schultheis, P Fisher, S Ramos, A Nunez, M Bernard, S Graham, V Martini, T Chrun, Y Xiao, JC Kash, JK Taubenberger, S Elliott, A Patel, P Beverley, P Rijal, DB Weiner, A Townsend, KE Broderick, E Tchilian |
Journal of immunology (Baltimore, Md. : 1950) | 2020 |
Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice
CM Bliss, AJ Parsons, R Nachbagauer, JR Hamilton, F Cappuccini, M Ulaszewska, JP Webber, A Clayton, AV Hill, L Coughlan |
Molecular Therapy — Methods & Clinical Development | 2020 |
Influenza A Virus Antibodies with Antibody-Dependent Cellular Cytotoxicity Function
R Gao, Z Sheng, CC Sreenivasan, D Wang, F Li |
Viruses | 2020 |
Adeno‐associated virus‐vectored influenza vaccine elicits neutralizing and Fcγ receptor‐activating antibodies
DE Demminger, L Walz, K Dietert, H Hoffmann, O Planz, AD Gruber, V Messling, T Wolff |
EMBO Molecular Medicine | 2020 |
The potential danger of suboptimal antibody responses in COVID-19
A Iwasaki, Y Yang |
Nature Reviews Immunology | 2020 |
The Transcription Factor T-bet Resolves Memory B Cell Subsets with Distinct Tissue Distributions and Antibody Specificities in Mice and Humans
JL Johnson, RL Rosenthal, JJ Knox, A Myles, MS Naradikian, J Madej, M Kostiv, AM Rosenfeld, W Meng, SR Christensen, SE Hensley, J Yewdell, DH Canaday, J Zhu, AB McDermott, Y Dori, M Itkin, EJ Wherry, N Pardi, D Weissman, A Naji, ET Prak, MR Betts, MP Cancro |
Immunity | 2020 |
Viruses to fight other viruses: the influenza vaccine case
JA Bengoechea |
EMBO Molecular Medicine | 2020 |
Influenza vaccination strategies targeting the hemagglutinin stem region
H Fukuyama, R Shinnakasu, T Kurosaki |
Immunological Reviews | 2020 |
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
J Hansen, A Baum, KE Pascal, V Russo, S Giordano, E Wloga, BO Fulton, Y Yan, K Koon, K Patel, KM Chung, A Hermann, E Ullman, J Cruz, A Rafique, T Huang, J Fairhurst, C Libertiny, M Malbec, W Lee, R Welsh, G Farr, S Pennington, D Deshpande, J Cheng, A Watty, P Bouffard, R Babb, N Levenkova, C Chen, B Zhang, AR Hernandez, K Saotome, Y Zhou, M Franklin, S Sivapalasingam, DC Lye, S Weston, J Logue, R Haupt, M Frieman, G Chen, W Olson, AJ Murphy, N Stahl, GD Yancopoulos, CA Kyratsous |
Science | 2020 |
Murine Cross-Reactive Nonneutralizing Polyclonal IgG1 Antibodies Induced by Influenza Vaccine Inhibit the Cross-Protective Effect of IgG2 against Heterologous Virus in Mice
M Shibuya, T Aoshi, E Kuroda, Y Yoshioka, S Schultz-Cherry |
Journal of virology | 2020 |
Protection From Influenza by Intramuscular Gene Vector Delivery of a Broadly Neutralizing Nanobody Does Not Depend on Antibody Dependent Cellular Cytotoxicity
JM Rosario, M Smith, K Zaki, P Risley, N Temperton, OG Engelhardt, M Collins, Y Takeuchi, SE Hufton |
Frontiers in immunology | 2020 |
The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19
AH Mansourabadi, M Sadeghalvad, HR Mohammadi-Motlagh, N Rezaei |
Life Sciences | 2020 |
Prospects and Challenges in the Development of Universal Influenza Vaccines
A Madsen, RJ Cox |
Human vaccines | 2020 |
Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection
S Bournazos, D Corti, HW Virgin, JV Ravetch |
Nature | 2020 |
Subdominance in Antibody Responses: Implications for Vaccine Development
G Lindahl |
Microbiology and molecular biology reviews : MMBR | 2020 |
Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19
K Karthik, TM Senthilkumar, S Udhayavel, GD Raj |
Human Vaccines & Immunotherapeutics | 2020 |
Antibody-dependent cell-mediated cytotoxicity antibody responses to inactivated and live-attenuated influenza vaccination in children during 2014–15
K Florek, J Mutschler, HQ McLean, JP King, B Flannery, EA Belongia, TC Friedrich |
Vaccine | 2020 |
A Vaccine Displaying a Trimeric Influenza-A HA Stem Protein on Capsid-Like Particles Elicits Potent and Long-Lasting Protection in Mice
S Thrane, KL Aves, IE Uddbäck, CM Janitzek, J Han, YR Yang, AB Ward, TG Theander, MA Nielsen, A Salanti, AR Thomsen, JP Christensen, AF Sander |
Human vaccines | 2020 |
Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
WS Lee, AK Wheatley, SJ Kent, BJ DeKosky |
Nature Microbiology | 2020 |
Augmented reality in scientific visualization and communications: a new dawn of looking at antibody interactions
K Chan, J Poh, W Wu, S Gan |
2020 | |
Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo
A Schäfer, F Muecksch, J Lorenzi, S Leist, M Cipolla, S Bournazos, F Schmidt, R Maison, A Gazumyan, D Martinez, R Baric, D Robbiani, T Hatziioannou, J Ravetch, P Bieniasz, R Bowen, M Nussenzweig, T Sheahan |
Journal of Experimental Medicine | 2020 |
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology
L Piccoli, Y Park, M Tortorici, N Czudnochowski, A Walls, M Beltramello, C Silacci-Fregni, D Pinto, L Rosen, J Bowen, O Acton, S Jaconi, B Guarino, A Minola, F Zatta, N Sprugasci, J Bassi, A Peter, A Marco, J Nix, F Mele, S Jovic, B Rodriguez, S Gupta, F Jin, G Piumatti, G Presti, A Pellanda, M Biggiogero, M Tarkowski, M Pizzuto, E Cameroni, C Havenar-Daughton, M Smithey, D Hong, V Lepori, E Albanese, A Ceschi, E Bernasconi, L Elzi, P Ferrari, C Garzoni, A Riva, G Snell, F Sallusto, K Fink, H Virgin, A Lanzavecchia, D Corti, D Veesler |
Cell | 2020 |
Chimeric hemagglutinin vaccine elicits broadly protective CD4 and CD8 T cell responses against multiple influenza strains and subtypes
Liao HY, Wang SC, Ko YA, Lin KI, Ma C, Cheng TJ, Wong CH |
Proceedings of the National Academy of Sciences | 2020 |
Characterization of Novel Cross-Reactive Influenza B Virus Hemagglutinin Head Specific Antibodies That Lack Hemagglutination Inhibition Activity.
Kirkpatrick E, Henry C, McMahon M, Jiang K, Strohmeier S, van Bakel H, Wilson PC, Krammer F |
Journal of virology | 2020 |
Engineered Recombinant Single Chain Variable Fragment of Monoclonal Antibody Provides Protection to Chickens Infected with H9N2 Avian Influenza.
Lukosaityte D, Sadeyen JR, Shrestha A, Sealy JE, Bhat S, Chang P, Digard P, Iqbal M |
Human vaccines | 2020 |
Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection in vivo.
Schäfer A, Muecksch F, Lorenzi JCC, Leist SR, Cipolla M, Bournazos S, Schmidt F, Gazumyan A, Baric RS, Robbiani DF, Hatziioannou T, Ravetch JV, Bieniasz PD, Nussenzweig MC, Sheahan TP |
bioRxiv : the preprint server for biology | 2020 |
Functional diversification of IgGs through Fc glycosylation
Taia Wang, Jeffrey Ravetch |
Journal of Clinical Investigation | 2019 |
Selective induction of antibody effector functional responses using MF59-adjuvanted vaccination
Carolyn M Boudreau, Wen-Han Yu, Todd J. Suscovich, H Keipp Talbot, Kathryn Edwards, Galit Alter |
Journal of Clinical Investigation | 2019 |
Exposure of an occluded hemagglutinin epitope drives selection of a class of cross-protective influenza antibodies
Y Adachi, K Tonouchi, A Nithichanon, M Kuraoka, A Watanabe, R Shinnakasu, H Asanuma, A Ainai, Y Ohmi, T Yamamoto, KJ Ishii, H Hasegawa, H Takeyama, G Lertmemongkolchai, T Kurosaki, M Ato, G Kelsoe, Y Takahashi |
Nature Communications | 2019 |
The Multifaceted B Cell Response to Influenza Virus
JH Lam, N Baumgarth |
Journal of immunology (Baltimore, Md. : 1950) | 2019 |
The Quest for a Truly Universal Influenza Vaccine
YH Jang, BL Seong |
Frontiers in Cellular and Infection Microbiology | 2019 |
Antiviral Functions of Monoclonal Antibodies against Chikungunya Virus
J Jin, G Simmons |
Viruses | 2019 |
T and B Cell Immune Responses to Influenza Viruses in Pigs
B Holzer, V Martini, M Edmans, E Tchilian |
Frontiers in immunology | 2019 |
A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface
S Bangaru, S Lang, M Schotsaert, HA Vanderven, X Zhu, N Kose, R Bombardi, JA Finn, SJ Kent, P Gilchuk, I Gilchuk, HL Turner, A García-Sastre, S Li, AB Ward, IA Wilson, JE Crowe |
Cell | 2019 |
Quantifying Antibody Responses Induced by Antigen-Agnostic Immunotherapies
JP van Vloten, EM Klafuric, K Karimi, G McFadden, JJ Petrik, SK Wootton, BW Bridle |
Molecular Therapy — Methods & Clinical Development | 2019 |
Antibody-Dependent Cellular Phagocytosis in Antiviral Immune Responses
MZ Tay, K Wiehe, J Pollara |
Frontiers in immunology | 2019 |
Extra-Neutralizing FcR-Mediated Antibody Functions for a Universal Influenza Vaccine
CM Boudreau, G Alter |
Frontiers in immunology | 2019 |
Understudied Factors Influencing Fc-Mediated Immune Responses against Viral Infections
SP Anand, A Finzi |
Human vaccines | 2019 |
Differential requirements for FcγR engagement by protective antibodies against Ebola virus
S Bournazos, DJ DiLillo, AJ Goff, PJ Glass, JV Ravetch |
Proceedings of the National Academy of Sciences | 2019 |
Influenza H7N9 Virus Neuraminidase-Specific Human Monoclonal Antibodies Inhibit Viral Egress and Protect from Lethal Influenza Infection in Mice
IM Gilchuk, S Bangaru, P Gilchuk, RP Irving, N Kose, RG Bombardi, NJ Thornburg, CB Creech, KM Edwards, S Li, HL Turner, W Yu, X Zhu, IA Wilson, AB Ward, JE Crowe |
Cell Host & Microbe | 2019 |
Outflanking immunodominance to target subdominant broadly neutralizing epitopes
D Angeletti, I Kosik, JJ Santos, WT Yewdell, CM Boudreau, VV Mallajosyula, MC Mankowski, M Chambers, M Prabhakaran, HD Hickman, AB McDermott, G Alter, J Chaudhuri, JW Yewdell |
Proceedings of the National Academy of Sciences | 2019 |
Influenza and Antibody-Dependent Cellular Cytotoxicity
TA Holle, MA Moody |
Frontiers in immunology | 2019 |
Broadly Inhibiting Antineuraminidase Monoclonal Antibodies Induced by Trivalent Influenza Vaccine and H7N9 Infection in Humans
P Rijal, BB Wang, TK Tan, L Schimanski, P Janesch, T Dong, JW McCauley, RS Daniels, AR Townsend, KY Huang, S Schultz-Cherry |
Journal of virology | 2019 |
Enhancing the cross protective efficacy of live attenuated influenza virus vaccine by supplemented vaccination with M2 ectodomain virus-like particles
YT Lee, KH Kim, EJ Ko, MC Kim, YN Lee, HS Hwang, Y Lee, YJ Jung, YJ Kim, J Santos, DR Perez, SM Kang |
Virology | 2019 |
The use of cell-mediated immunity for the evaluation of influenza vaccines: an upcoming necessity
E Gianchecchi, A Torelli, E Montomoli |
Human Vaccines & Immunotherapeutics | 2019 |
Cross-lineage protection by human antibodies binding the influenza B hemagglutinin
Y Liu, HX Tan, M Koutsakos, S Jegaskanda, R Esterbauer, D Tilmanis, M Aban, K Kedzierska, AC Hurt, SJ Kent, AK Wheatley |
Nature Communications | 2019 |
Neuraminidase inhibition contributes to influenza A virus neutralization by anti-hemagglutinin stem antibodies
I Kosik, D Angeletti, JS Gibbs, M Angel, K Takeda, M Kosikova, V Nair, HD Hickman, H Xie, CB Brooke, JW Yewdell |
Journal of Experimental Medicine | 2019 |
Characterization of Mouse Monoclonal Antibodies Against the HA of A(H7N9) Influenza Virus
M Ito, S Yamayoshi, K Murakami, K Saito, A Motojima, K Nakaishi, Y Kawaoka |
Viruses | 2019 |
Egg-based influenza split virus vaccine with monoglycosylation induces cross-strain protection against influenza virus infections
YC Tseng, CY Wu, ML Liu, TH Chen, WL Chiang, YH Yu, JT Jan, KI Lin, CH Wong, C Ma |
Proceedings of the National Academy of Sciences | 2019 |
The human antibody response to influenza A virus infection and vaccination
F Krammer |
Nature Reviews Immunology | 2019 |
Broad and Protective Influenza B Virus Neuraminidase Antibodies in Humans after Vaccination and their Clonal Persistence as Plasma Cells
MS Piepenbrink, A Nogales, M Basu, CF Fucile, JL Liesveld, MC Keefer, AF Rosenberg, L Martinez-Sobrido, JJ Kobie, A Moscona |
mBio | 2019 |
Influenza Hemagglutinin and Neuraminidase: Yin–Yang Proteins Coevolving to Thwart Immunity
I Kosik, JW Yewdell |
Viruses | 2019 |
“Breathing” Hemagglutinin Reveals Cryptic Epitopes for Universal Influenza Vaccine Design
Y Wu, GF Gao |
Cell | 2019 |
Universal Influenza Virus Vaccines That Target the Conserved Hemagglutinin Stalk and Conserved Sites in the Head Domain
F Krammer, P Palese |
The Journal of Infectious Diseases | 2019 |
Drugs for Influenza Treatment: Is There Significant News?
N Principi, B Camilloni, A Alunno, I Polinori, A Argentiero, S Esposito |
Frontiers in Medicine | 2019 |
Antibodies to a Conserved Influenza Head Interface Epitope Protect by an IgG Subtype-Dependent Mechanism
A Watanabe, KR McCarthy, M Kuraoka, AG Schmidt, Y Adachi, T Onodera, K Tonouchi, TM Caradonna, G Bajic, S Song, CE McGee, GD Sempowski, F Feng, P Urick, TB Kepler, Y Takahashi, SC Harrison, G Kelsoe |
Cell | 2019 |
Protective Antibodies Against Influenza Proteins
HO Padilla-Quirarte, DV Lopez-Guerrero, L Gutierrez-Xicotencatl, F Esquivel-Guadarrama |
Frontiers in immunology | 2019 |
Targeting Conventional Dendritic Cells to Fine-Tune Antibody Responses
DY Tesfaye, A Gudjonsson, B Bogen, E Fossum |
Frontiers in immunology | 2019 |
Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase
F Broecker, A Zheng, N Suntronwong, W Sun, MJ Bailey, F Krammer, P Palese, TS Dermody |
Journal of virology | 2019 |
A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation
S Fischinger, JK Fallon, AR Michell, T Broge, TJ Suscovich, H Streeck, G Alter |
Journal of Immunological Methods | 2019 |
Germline-Encoded Affinity for Cognate Antigen Enables Vaccine Amplification of a Human Broadly Neutralizing Response against Influenza Virus
M Sangesland, L Ronsard, SW Kazer, J Bals, S Boyoglu-Barnum, AS Yousif, R Barnes, J Feldman, M Quirindongo-Crespo, PM McTamney, D Rohrer, N Lonberg, B Chackerian, BS Graham, M Kanekiyo, AK Shalek, D Lingwood |
Immunity | 2019 |
Fcγ Receptors Contribute to the Antiviral Properties of Influenza Virus Neuraminidase-Specific Antibodies
ER Job, T Ysenbaert, A Smet, AV Hecke, L Meuris, H Kleanthous, X Saelens, TU Vogel, P Palese |
mBio | 2019 |
Antibody-Dependent Natural Killer Cell Activation After Ebola Vaccination
HR Wagstaffe, EA Clutterbuck, V Bockstal, JN Stoop, K Luhn, M Douoguih, G Shukarev, MD Snape, AJ Pollard, EM Riley, MR Goodier |
The Journal of Infectious Diseases | 2019 |
Neuraminidase expressing virus-like particle vaccine provides effective cross protection against influenza virus
KH Kim, YT Lee, S Park, YJ Jung, Y Lee, EJ Ko, YJ Kim, X Li, SM Kang |
Virology | 2019 |
Non-neutralizing Antibodies Directed at Conservative Influenza Antigens
Sedova ES, Scherbinin DN, Lysenko AA, Alekseeva SV, Artemova EA, Shmarov MM |
Acta Naturae | 2019 |
Immunity to Influenza Infection in Humans
DJ Topham, ML DeDiego, A Nogales, MY Sangster, A Sant |
Cold Spring Harbor Perspectives in Medicine | 2019 |
Integrative Physiology of Pneumonia
LJ Quinton, AJ Walkey, JP Mizgerd |
Physiological reviews | 2018 |
Universal Influenza Vaccines: Progress in Achieving Broad Cross-Protection In Vivo
SL Epstein |
American Journal of Epidemiology | 2018 |
Treating Influenza Infection, From Now and Into the Future
S Davidson |
Frontiers in immunology | 2018 |
The Unexpected Impact of Vaccines on Secondary Bacterial Infections Following Influenza
AM Smith, VC Huber |
Viral Immunology | 2018 |
Combination of M2e peptide with stalk HA epitopes of influenza A virus enhances protective properties of recombinant vaccine
LM Tsybalova, LA Stepanova, MA Shuklina, ES Mardanova, RY Kotlyarov, MV Potapchuk, SA Petrov, EA Blokhina, NV Ravin, S Pöhlmann |
PloS one | 2018 |
Passive immunization with influenza haemagglutinin specific monoclonal antibodies
R Rudraraju, K Subbarao |
Human Vaccines & Immunotherapeutics | 2018 |
Mini-hemagglutinin vaccination induces cross-reactive antibodies in pre-exposed NHP that protect mice against lethal influenza challenge
JE van der Lubbe, J Huizingh, JW Verspuij, L Tettero, SP Schmit-Tillemans, P Mooij, D Mortier, G Koopman, WM Bogers, L Dekking, W Meijberg, T Kwaks, B Brandenburg, JT Tolboom, H Schuitemaker, R Roozendaal, H Kuipers, RC Zahn |
npj Vaccines | 2018 |
Human protective monoclonal antibodies against the HA stem of group 2 HAs derived from an H3N2 virus-infected human
S Yamayoshi, M Ito, R Uraki, T Sasaki, K Ikuta, Y Kawaoka |
Journal of Infection | 2018 |
Influenza
F Krammer, GJ Smith, RA Fouchier, M Peiris, K Kedzierska, PC Doherty, P Palese, ML Shaw, J Treanor, RG Webster, A García-Sastre |
Nature Reviews Disease Primers | 2018 |
Distinct and complementary roles of CD4 T cells in protective immunity to influenza virus
AJ Sant, KA Richards, J Nayak |
Current Opinion in Immunology | 2018 |
Comprehensive analysis of N -glycans in IgG purified from ferrets with or without influenza A virus infection
G Zou, M Kosikova, SR Kim, S Kotian, WW Wu, R Shen, DN Powers, C Agarabi, H Xie, T Ju |
The Journal of biological chemistry | 2018 |
Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies
YQ Chen, TJ Wohlbold, NY Zheng, M Huang, Y Huang, KE Neu, J Lee, H Wan, KT Rojas, E Kirkpatrick, C Henry, AK Palm, CT Stamper, LY Lan, DJ Topham, J Treanor, J Wrammert, R Ahmed, MC Eichelberger, G Georgiou, F Krammer, PC Wilson |
Cell | 2018 |
A Highly Potent and Broadly Neutralizing H1 Influenza-Specific Human Monoclonal Antibody
A Nogales, MS Piepenbrink, J Wang, S Ortega, M Basu, CF Fucile, JJ Treanor, AF Rosenberg, MS Zand, MC Keefer, L Martinez-Sobrido, JJ Kobie |
Scientific Reports | 2018 |
Immunological responses to influenza vaccination: lessons for improving vaccine efficacy
, S Bournazos, JV Ravetch |
Current Opinion in Immunology | 2018 |
How single mutations affect viral escape from broad and narrow antibodies to H1 influenza hemagglutinin
MB Doud, JM Lee, JD Bloom |
Nature Communications | 2018 |
The Potential Role of Fc-Receptor Functions in the Development of a Universal Influenza Vaccine
S Jegaskanda |
Human vaccines | 2018 |
Antibody Immunodominance: The Key to Understanding Influenza Virus Antigenic Drift
MO Altman, D Angeletti, JW Yewdell |
Viral Immunology | 2018 |
A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus
BM Gunn, WH Yu, MM Karim, JM Brannan, AS Herbert, AZ Wec, PJ Halfmann, ML Fusco, SL Schendel, K Gangavarapu, T Krause, X Qiu, S He, J Das, TJ Suscovich, J Lai, K Chandran, L Zeitlin, JE Crowe, D Lauffenburger, Y Kawaoka, GP Kobinger, KG Andersen, JM Dye, EO Saphire, G Alter |
Cell Host & Microbe | 2018 |
Therapeutic Administration of Broadly Neutralizing FI6 Antibody Reveals Lack of Interaction Between Human IgG1 and Pig Fc Receptors
SB Morgan, B Holzer, JD Hemmink, FJ Salguero, JC Schwartz, G Agatic, E Cameroni, B Guarino, E Porter, P Rijal, A Townsend, B Charleston, D Corti, E Tchilian |
Frontiers in immunology | 2018 |
Anti-influenza Hyperimmune Immunoglobulin Enhances Fc-functional Antibody Immunity during Human Influenza Infection
HA Vanderven, K Wragg, F Ana-Sosa-Batiz, AB Kristensen, S Jegaskanda, AK Wheatley, D Wentworth, BD Wines, PM Hogarth, S Rockman, SJ Kent |
The Journal of Infectious Diseases | 2018 |
Characterization of Hemagglutinin Antigens on Influenza Virus and within Vaccines Using Electron Microscopy
J Gallagher, D McCraw, U Torian, N Gulati, M Myers, M Conlon, A Harris |
Human vaccines | 2018 |
Asymmetric antiviral effects of ebolavirus antibodies targeting glycoprotein stem and glycan cap
PA Ilinykh, RI Santos, BM Gunn, NA Kuzmina, X Shen, K Huang, P Gilchuk, AI Flyak, P Younan, G Alter, JE Crowe, A Bukreyev, JH Kuhn |
PLoS pathogens | 2018 |
Roles of Fc Domain and Exudation in L2 Antibody-Mediated Protection against Human Papillomavirus
JW Wang, WH Wu, TC Huang, M Wong, K Kwak, K Ozato, CF Hung, RB Roden, L Banks |
Journal of virology | 2018 |
Cross-reactive mouse monoclonal antibodies raised against the hemagglutinin of A/Shanghai/1/2013 (H7N9) protect against novel H7 virus isolates in the mouse model
D Stadlbauer, F Amanat, S Strohmeier, R Nachbagauer, F Krammer |
Emerging Microbes & Infections | 2018 |
Development of a high-throughput assay to detect antibody inhibition of low pH induced conformational changes of influenza virus hemagglutinin
JF Trost, EH LeMasters, F Liu, P Carney, X Lu, K Sugawara, S Hongo, J Stevens, DA Steinhauer, T Tumpey, JM Katz, MZ Levine, ZN Li, F Krammer |
PloS one | 2018 |
The Role of Fc Gamma Receptors in Broad Protection against Influenza Viruses
N Thulin, T Wang |
Human vaccines | 2018 |
Heterosubtypic influenza protection elicited by double-layered polypeptide nanoparticles in mice
L Deng, TZ Chang, Y Wang, S Li, S Wang, S Matsuyama, G Yu, RW Compans, JD Li, MR Prausnitz, JA Champion, BZ Wang |
Proceedings of the National Academy of Sciences | 2018 |
Double-layered protein nanoparticles induce broad protection against divergent influenza A viruses
L Deng, T Mohan, TZ Chang, GX Gonzalez, Y Wang, YM Kwon, SM Kang, RW Compans, JA Champion, BZ Wang |
Nature Communications | 2018 |
Avian Influenza A Virus Pandemic Preparedness and Vaccine Development
R de Vries, S Herfst, M Richard |
Human vaccines | 2018 |
Comparison of Adjuvanted-Whole Inactivated Virus and Live-Attenuated Virus Vaccines against Challenge with Contemporary, Antigenically Distinct H3N2 Influenza A Viruses
EJ Abente, DS Rajao, J Santos, BS Kaplan, TL Nicholson, SL Brockmeier, PC Gauger, DR Perez, AL Vincent, S Schultz-Cherry |
Journal of virology | 2018 |
A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies
MJ Bailey, F Broecker, PE Leon, GS Tan |
Journal of visualized experiments : JoVE | 2018 |
Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model
MJ Bailey, J Duehr, H Dulin, F Broecker, JA Brown, FO Arumemi, MC González, VH Leyva-Grado, MJ Evans, V Simon, JK Lim, F Krammer, R Hai, P Palese, GS Tan |
Nature Communications | 2018 |
A unique nanoparticulate TLR9 agonist enables a HA split vaccine to confer FcγR-mediated protection against heterologous lethal influenza virus infection
T Yamamoto, Y Masuta, M Momota, M Kanekiyo, T Kanuma, S Takahama, E Moriishi, Y Yasutomi, T Saito, BS Graham, Y Takahashi, KJ Ishii |
International Immunology | 2018 |
Antibody Responses toward the Major Antigenic Sites of Influenza B Virus Hemagglutinin in Mice, Ferrets, and Humans
W Sun, DS Kang, A Zheng, ST Liu, F Broecker, V Simon, F Krammer, P Palese, TS Dermody |
Journal of virology | 2018 |
Broadened immunity against influenza by vaccination with computationally designed influenza virus N1 neuraminidase constructs
ER Job, T Ysenbaert, A Smet, I Christopoulou, T Strugnell, EO Oloo, RP Oomen, H Kleanthous, TU Vogel, X Saelens |
npj Vaccines | 2018 |
Influenza Virus Infection Enhances Antibody-Mediated NK Cell Functions via Type I Interferon-Dependent Pathways
S Jegaskanda, HA Vanderven, HX Tan, S Alcantara, KM Wragg, MS Parsons, AW Chung, JA Juno, SJ Kent, S Schultz-Cherry |
Journal of virology | 2018 |
Fc functional antibodies during severe human H7N9 and seasonal influenza
Hillary Vanderven, Lu Liu, Fernanda Ana-Sosa-Batiz, Thi HO Nguyen, yanmin wan, Bruce Wines, Mark Hogarth, Danielle Tilmanis, Arnold Reynaldi, Matthew Parsons, Aaron C. Hurt, Miles Davenport, Tom Kotsimbos, Allen Cheng, Katherine Kedzierska, xiaoyan zhang, Jianqing Xu, Stephen Kent |
JCI Insight | 2017 |
Beyond Viral Neutralization
GK Lewis, M Pazgier, DT Evans, G Ferrari, S Bournazos, MS Parsons, NF Bernard, A Finzi |
AIDS Research and Human Retroviruses | 2017 |
Signaling by Antibodies: Recent Progress
S Bournazos, TT Wang, R Dahan, J Maamary, JV Ravetch |
Annual Review of Immunology | 2017 |
Hierarchical and Redundant Roles of Activating FcγRs in Protection against Influenza Disease by M2e-Specific IgG1 and IgG2a Antibodies
SV Hoecke, K Ehrhardt, A Kolpe, KE Bakkouri, L Deng, H Grootaert, S Schoonooghe, A Smet, M Bentahir, K Roose, M Schotsaert, B Schepens, N Callewaert, F Nimmerjahn, P Staeheli, H Hengel, X Saelens, S Schultz-Cherry |
Journal of virology | 2017 |
A Broadly Reactive Human Anti-hemagglutinin Stem Monoclonal Antibody That Inhibits Influenza A Virus Particle Release
S Yamayoshi, R Uraki, M Ito, M Kiso, S Nakatsu, A Yasuhara, K Oishi, T Sasaki, K Ikuta, Y Kawaoka |
EBioMedicine | 2017 |
Intravenous Immunoglobulin Protects Against Severe Pandemic Influenza Infection
S Rockman, S Lowther, S Camuglia, K Vandenberg, S Taylor, L Fabri, S Miescher, M Pearse, D Middleton, SJ Kent, D Maher |
EBioMedicine | 2017 |
In Vitro Neutralization Is Not Predictive of Prophylactic Efficacy of Broadly Neutralizing Monoclonal Antibodies CR6261 and CR9114 against Lethal H2 Influenza Virus Challenge in Mice
TC Sutton, EW Lamirande, KW Bock, IN Moore, W Koudstaal, M Rehman, GJ Weverling, J Goudsmit, K Subbarao, A García-Sastre |
Journal of virology | 2017 |
Protective efficacy of influenza group 2 hemagglutinin stem-fragment immunogen vaccines
TC Sutton, S Chakraborty, VV Mallajosyula, EW Lamirande, K Ganti, KW Bock, IN Moore, R Varadarajan, K Subbarao |
npj Vaccines | 2017 |
Structural Insight into a Human Neutralizing Antibody against Influenza Virus H7N9
C Chen, L Liu, Y Xiao, S Cui, J Wang, Q Jin, RM Sandri-Goldin |
Journal of virology | 2017 |
IL-6 Production by TLR-Activated APC Broadly Enhances Aged Cognate CD4 Helper and B Cell Antibody Responses In Vivo
V Brahmakshatriya, Y Kuang, P Devarajan, J Xia, W Zhang, AM Vong, SL Swain |
Journal of immunology (Baltimore, Md. : 1950) | 2017 |
The establishment of surrogates and correlates of protection: Useful tools for the licensure of effective influenza vaccines?
BJ Ward, S Pillet, N Charland, S Trepanier, J Couillard, N Landry |
Human Vaccines & Immunotherapeutics | 2017 |
Pandemic 2009 H1N1 Influenza Venus reporter virus reveals broad diversity of MHC class II-positive antigen-bearing cells following infection in vivo
A DiPiazza, A Nogales, N Poulton, PC Wilson, L Martínez-Sobrido, AJ Sant |
Scientific Reports | 2017 |
Sudan ebolavirus long recovered survivors produce GP-specific Abs that are of the IgG1 subclass and preferentially bind FcγRI
O Radinsky, A Edri, M Brusilovsky, S Fedida-Metula, A Sobarzo, O Gershoni-Yahalom, J Lutwama, J Dye, L Lobel, A Porgador |
Scientific Reports | 2017 |
A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action
N Chai, LR Swem, S Park, G Nakamura, N Chiang, A Estevez, R Fong, L Kamen, E Kho, M Reichelt, Z Lin, H Chiu, E Skippington, Z Modrusan, J Stinson, M Xu, P Lupardus, C Ciferri, MW Tan |
Nature Communications | 2017 |
From Original Antigenic Sin to the Universal Influenza Virus Vaccine
C Henry, AK Palm, F Krammer, PC Wilson |
Trends in Immunology | 2017 |
A Potent Germline-like Human Monoclonal Antibody Targets a pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin
F Yu, H Song, Y Wu, SY Chang, L Wang, W Li, B Hong, S Xia, C Wang, S Khurana, Y Feng, Y Wang, Z Sun, B He, D Hou, J Manischewitz, LR King, Y Song, JY Min, H Golding, X Ji, L Lu, S Jiang, DS Dimitrov, T Ying |
Cell Host & Microbe | 2017 |
Non-Neutralizing Antibodies Directed against HIV and Their Functions
LM Mayr, B Su, C Moog |
Frontiers in immunology | 2017 |
Immune history and influenza virus susceptibility
S Cobey, SE Hensley |
Current Opinion in Virology | 2017 |
Conserved epitope on influenza-virus hemagglutinin head defined by a vaccine-induced antibody
DD Raymond, G Bajic, J Ferdman, P Suphaphiphat, EC Settembre, MA Moody, AG Schmidt, SC Harrison |
Proceedings of the National Academy of Sciences | 2017 |
Is It Possible to Develop a “Universal” Influenza Virus Vaccine?: Outflanking Antibody Immunodominance on the Road to Universal Influenza Vaccination
D Angeletti, JW Yewdell |
Cold Spring Harbor perspectives in biology | 2017 |
Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins
R Nachbagauer, A Choi, A Hirsh, I Margine, S Iida, A Barrera, M Ferres, RA Albrecht, A García-Sastre, NM Bouvier, K Ito, RA Medina, P Palese, F Krammer |
Nature Immunology | 2017 |
Modulating IgG effector function by Fc glycan engineering
T Li, DJ DiLillo, S Bournazos, JP Giddens, JV Ravetch, LX Wang |
Proceedings of the National Academy of Sciences | 2017 |
Fc or not Fc; that is the question: Antibody Fc-receptor interactions are key to universal influenza vaccine design
S Jegaskanda, HA Vanderven, AK Wheatley, SJ Kent |
Human Vaccines & Immunotherapeutics | 2017 |
Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice
W He, CJ Chen, CE Mullarkey, JR Hamilton, CK Wong, PE Leon, MB Uccellini, V Chromikova, C Henry, KW Hoffman, JK Lim, PC Wilson, MS Miller, F Krammer, P Palese, GS Tan |
Nature Communications | 2017 |
Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes
TJ Wohlbold, KA Podolsky, V Chromikova, E Kirkpatrick, V Falconieri, P Meade, F Amanat, J Tan, BR tenOever, GS Tan, S Subramaniam, P Palese, F Krammer |
Nature Microbiology | 2017 |
A modified vaccinia Ankara vaccine vector expressing a mosaic H5 hemagglutinin reduces viral shedding in rhesus macaques
NW Florek, A Kamlangdee, JP Mutschler, B Kingstad-Bakke, N Schultz-Darken, KW Broman, JE Osorio, TC Friedrich, S Pöhlmann |
PloS one | 2017 |
Conformational modulation of influenza virus hemagglutinin: characterization and in vivo efficacy of monomeric form
JH Seok, J Kim, DB Lee, KJ Cho, JH Lee, G Bae, MS Chung, KH Kim |
Scientific Reports | 2017 |
An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody protects mice from morbidity without interfering with the development of protective immunity to subsequent homologous challenge
JR Wilson, JA Belser, J DaSilva, Z Guo, X Sun, S Gansebom, Y Bai, TJ Stark, J Chang, P Carney, MZ Levine, J Barnes, J Stevens, TR Maines, TM Tumpey, IA York |
Virology | 2017 |
Increasing the breadth and potency of response to the seasonal influenza virus vaccine by immune complex immunization
J Maamary, TT Wang, GS Tan, P Palese, JV Ravetch |
Proceedings of the National Academy of Sciences | 2017 |
In Vivo Production of Monoclonal Antibodies by Gene Transfer via Electroporation Protects against Lethal Influenza and Ebola Infections
CD Andrews, Y Luo, M Sun, J Yu, AJ Goff, PJ Glass, NN Padte, Y Huang, DD Ho |
Molecular Therapy - Methods & Clinical Development | 2017 |
Divergent Requirement of Fc-Fcγ Receptor Interactions for In Vivo Protection against Influenza Viruses by Two Pan-H5 Hemagglutinin Antibodies
S Wang, H Ren, W Jiang, H Chen, H Hu, Z Chen, P Zhou, S Perlman |
Journal of virology | 2017 |
The evolution of seasonal influenza viruses
VN Petrova, CA Russell |
Nature Reviews Microbiology | 2017 |
Primary Human Influenza B Virus Infection Induces Cross-Lineage Hemagglutinin Stalk–Specific Antibodies Mediating Antibody-Dependent Cellular Cytoxicity
RD de Vries, NJ Nieuwkoop, FR van der Klis, MP Koopmans, F Krammer, GF Rimmelzwaan |
The Journal of Infectious Diseases | 2017 |
Antibodies directed towards neuraminidase N1 control disease in a mouse model of influenza
ER Job, M Schotsaert, LI Ibañez, A Smet, T Ysenbaert, K Roose, M Dai, CA de Haan, H Kleanthous, TU Vogel, X Saelens |
Journal of virology | 2017 |
Tackling influenza with broadly neutralizing antibodies
Corti D, Cameroni E, Guarino B, Kallewaard NL, Zhu Q, Lanzavecchia A |
Current Opinion in Virology | 2017 |
Non-neutralizing antibodies induced by seasonal influenza vaccine prevent, not exacerbate A(H1N1)pdm09 disease
JH Kim, AJ Reber, A Kumar, P Ramos, G Sica, N Music, Z Guo, M Mishina, J Stevens, IA York, J Jacob, S Sambhara |
Scientific Reports | 2016 |
A Structural and Mathematical Modeling Analysis of the Likelihood of Antibody-Dependent Enhancement in Influenza
B Ramakrishnan, K Viswanathan, K Tharakaraman, V Dančík, R Raman, GJ Babcock, Z Shriver, R Sasisekharan |
Trends in Microbiology | 2016 |
Modulating Antibody Functionality in Infectious Disease and Vaccination
BM Gunn, G Alter |
Trends in Molecular Medicine | 2016 |
Immunoglobulin Glycosylation Effects in Allergy and Immunity
A Epp, KC Sullivan, AB Herr, RT Strait |
Current Allergy and Asthma Reports | 2016 |
Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes
NL Kallewaard, D Corti, PJ Collins, U Neu, JM McAuliffe, E Benjamin, L Wachter-Rosati, FJ Palmer-Hill, AQ Yuan, PA Walker, MK Vorlaender, S Bianchi, B Guarino, A De Marco, F Vanzetta, G Agatic, M Foglierini, D Pinna, B Fernandez-Rodriguez, A Fruehwirth, C Silacci, RW Ogrodowicz, SR Martin, F Sallusto, JA Suzich, A Lanzavecchia, Q Zhu, SJ Gamblin, JJ Skehel |
Cell | 2016 |
Commentary on ‘Dissecting the hemagglutinin head and stalk specific IgG antibody response in healthcare workers following pandemic H1N1 vaccination’
TM Ross |
npj Vaccines | 2016 |
Broadly Neutralizing Hemagglutinin Stalk-Specific Antibodies Induce Potent Phagocytosis of Immune Complexes by Neutrophils in an Fc-Dependent Manner
CE Mullarkey, MJ Bailey, DA Golubeva, GS Tan, R Nachbagauer, W He, KE Novakowski, DM Bowdish, MS Miller, P Palese |
mBio | 2016 |
Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact
PE Leon, W He, CE Mullarkey, MJ Bailey, MS Miller, F Krammer, P Palese, GS Tan |
Proceedings of the National Academy of Sciences | 2016 |
Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection
CJ Dunand, PE Leon, M Huang, A Choi, V Chromikova, IY Ho, GS Tan, J Cruz, A Hirsh, NY Zheng, CE Mullarkey, FA Ennis, M Terajima, JJ Treanor, DJ Topham, K Subbarao, P Palese, F Krammer, PC Wilson |
Cell Host & Microbe | 2016 |
HA Antibody-Mediated FcγRIIIa Activity Is Both Dependent on FcR Engagement and Interactions between HA and Sialic Acids
F Cox, T Kwaks, B Brandenburg, MH Koldijk, V Klaren, B Smal, HJ Korse, E Geelen, L Tettero, D Zuijdgeest, EJ Stoop, E Saeland, R Vogels, RH Friesen, W Koudstaal, J Goudsmit |
Frontiers in immunology | 2016 |
Generation and Protective Ability of Influenza Virus–Specific Antibody-Dependent Cellular Cytotoxicity in Humans Elicited by Vaccination, Natural Infection, and Experimental Challenge
S Jegaskanda, C Luke, HD Hickman, MY Sangster, WF Wieland-Alter, JM McBride, JW Yewdell, PF Wright, J Treanor, CM Rosenberger, K Subbarao |
The Journal of Infectious Diseases | 2016 |
Unmasking Stem-Specific Neutralizing Epitopes by Abolishing N-Linked Glycosylation Sites of Influenza Virus Hemagglutinin Proteins for Vaccine Design
WC Liu, JT Jan, YJ Huang, TH Chen, SC Wu, S Perlman |
Journal of virology | 2016 |
Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination
J Lee, DR Boutz, V Chromikova, MG Joyce, C Vollmers, K Leung, AP Horton, BJ DeKosky, CH Lee, JJ Lavinder, EM Murrin, C Chrysostomou, KH Hoi, Y Tsybovsky, PV Thomas, A Druz, B Zhang, Y Zhang, L Wang, WP Kong, D Park, LI Popova, CL Dekker, MM Davis, CE Carter, TM Ross, AD Ellington, PC Wilson, EM Marcotte, JR Mascola, GC Ippolito, F Krammer, SR Quake, PD Kwong, G Georgiou |
Nature Medicine | 2016 |
Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus
W He, GS Tan, CE Mullarkey, AJ Lee, MM Lam, F Krammer, C Henry, PC Wilson, AA Ashkar, P Palese, MS Miller |
Proceedings of the National Academy of Sciences | 2016 |
Human seasonal influenza A viruses induce H7N9-cross-reactive antibody-dependent cellular cytotoxicity (ADCC) antibodies that are directed towards the nucleoprotein
S Jegaskanda, MD Co, J Cruz, K Subbarao, FA Ennis, M Terajima |
The Journal of Infectious Diseases | 2016 |
The Role and Function of Fcγ Receptors on Myeloid Cells.
Bournazos S, Wang TT, Ravetch JV |
Microbiology spectrum | 2016 |